 |
| Scientific Director Susan Catalano works to develop Alzheimer's drug |
Cognition Therapeutics on the South Side has raised a $2.5 million series A1 financing that will advance its promising Alzheimer's compound to the next level of development. The therapy they developed selectively blocks the activity of the toxic form of the protein that interferes with memory and learning and should be effective at all stages of the disease. Toxic proteins play a crucial role in a large class of diseases and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Studies indicate that blocking the effects of this protein may halt or reverse Alzheimer's disease.
The new funding will elevate one or more of the company's compounds to Investigational New Drug (IND) candidate status. This latest funding effort was led by Golden Seeds, one of the largest angel investing groups in the country, and was syndicated with Southern California-based Tech Coast Angels.
But a Pittsburgh family, The Breedlove Limited Family Partnership and TMC Investment Company, was also among the investors in this round. Previous Pittsburgh investors also participated in the round including Ogden CAP Associates, M5Invest, the PLSG and Innovation Works. Scientific Director Susan Catalano says the company's Pittsburgh roots are very deep and they are excited to be an integral part of our business community.
Cognition Therapeutics
South Side
Golden Seeds
Tech Coast Angels
Metro Pittsburgh Real Estate
No comments:
Post a Comment